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Progression of secondary hyperparathyroidism involves dereg-
ulation of genes related to DNA and RNA stability.
Background. Renal secondary hyperparathyroidism in its
late stages becomes autonomous, so excessive parathyroid hor-
mone (PTH) secretion no longer responds to physiologic stimuli
or to aggressive medical treatment.
Methods. To gain molecular understanding of progression of
renal secondary hyperparathyroidism, normal and hyperplastic
parathyroid tissue with diffuse and nodular growth were ana-
lyzed. The results were also compared to parathyroid adenomas.
The analysis was performed by high-density oligonucleotide mi-
croarray and bidirectional subtraction library.
Results. Analysis of the DNA arrays found 16 overexpressed
and 132 repressed genes in the nodules while the subtraction
library produced 34 overexpressed and 40 repressed genes.
The differentially expressed genes between diffuse and nodu-
lar samples included some related to DNA stability and re-
pair (TALDO1, PRDX2, DDB1, XRCC1, and POLB), RNA
stability and degradation (OASL and AUF1), protein synthe-
sis and processing (PFDN5, HSPD1, and NACA), cell growth
(CDC25C and GRPR), and tumorigenesis and cell cycle (VIL2
and TPD52).
Conclusion. According to the function described for
the deregulated genes, when secondary hyperparathyroidism
becomes autonomous and refractory to treatment, RNA
degradation may be increased while DNA integrity may be
compromised. These two mechanisms, combined with dereg-
ulation of genes related to growth and differentiation show
the complex pathway of parathyroid glands’ evolution in re-
nal hyperparathyroidism and may explain the large amount
of molecular cytogenetic aberrations found in refractory hy-
perparathyroidism. Considering that some of the genes with
altered expression in nodular hyperplasia lead to irreversible
consequences in the genomic integrity of the cells, an adequate
and early management of the secondary hyperparathyroidism
of chronic kidney disease becomes mandatory.
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Hyperplasia of the parathyroid glands is a common
secondary event occurring in patients with chronic kid-
ney disease [1]. As a result, parathyroid hormone (PTH)
secretion increases, causing clinical problems such as
hypercalcemia, bone disease, or vascular and valvular
calcifications [2, 3]. In early stages, this is a reversible
phenomenon, and the overexpression of PTH can still
be controlled by calcium, phosphate, and calcitriol [4].
Nevertheless, in the late stages of this disease, the ex-
cessive PTH secretion and the gland growth no longer
responds to biophysiologic influences or to aggressive
medical treatment [5, 6]. Even after kidney transplan-
tation, some patients do not recover and worsen their
parathyroid hyperplasia with a nonresponsive behavior
[7, 8].
Little is known about the changes that can take place in
the parathyroid cells. It has been reported that the major-
ity of surgically removed uremic parathyroid glands are
monoclonal neoplasms with nodular growth, as assessed
by X chromosome inactivation analysis [9–11]. Mono-
clonality suggests that genes involved in cell proliferation
could be deregulated, with the final effect being nodular
overgrowth of the glands. So far, there are not clear can-
didate genes responsible for this phenomenon [12]. Few
studies with no conclusive results have been published
with the purpose of identifying chromosomal regions that
may harbor putative parathyroid tumor suppressor genes
[13]. In a report using Comparative Genomic Hybridiza-
tion (CGH) and genome-wide allelotyping, it was found
that chromosomal changes and allelic losses were com-
mon in a series of 30 uremic patients with secondary or
tertiary (refractory) hyperparathyroidism [13].
Furthermore, a blind retrospective CGH study on two
cohorts of samples from patients with advanced sec-
ondary and tertiary hyperparathyroidism concluded that
recurrent clonal chromosomal changes are present in
more than half of the glands from the patients, support-
ing the idea of the monoclonal neoplastic nature of this
disorder [14].
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Table 1. Clinical data from patients who underwent parathyroidectomy or thyroidectomy
Sample Gender Age Diagnosis
C1 F 22 TA
C2 F 71 MG
Sample Gender Age Etiology Transplant PTH pg/mL Ca mg/dL P mg/dL
D1 M 30 CKDe Yesc 2351 12.4 10.1
D2 + D3 M 24 CKDf Noa 500 10.3 7.7
D4 F 21 CKDf Noa 2389 10.5 8.3
D5 + D6 M 12 CKDg No 2500 10.2 5.5
D7 M 61 CKDg Yesb 1000 9.4 10.0
D8 M 29 CKDe No 1191 9.7 10.8
N1 + N4 M 76 CKDf No 1300 10.9 3.8
N2 M 66 CKDe No 950 11.1 2.1
N3 F 58 CKDf No 1287 10.1 7.2
N5 F 54 CKDh Noa 2345 10.3 6.3
N6 M 40 CKDe Yesd 1700 10.0 6.2
N7 + N8 F 63 CKDf Yesb 755 10.5 2
Sample Gender Age Diagnosis Sestamibi scan PTH pg/mL Ca mg/dL P mg/dL
A1 M 20 RL + 142 13.4 2.1
A2 M 42 UR + 165 11.1 1.3
A3 F 73 OP + 280 12.0 2.1
A4 F 67 UR + 403 12.8 1.7
A5 F 58 OP + 220 11.6 2.3
A6 F 63 OP − 180 11.4 3.3
A7 F 60 OP − 188 11.8 2.5
A8 F 66 OP + 219 10.9 2.5
A9 F 59 OP + 275 11.9 2.4
Abbreviations are: PTH, parathyroid hormone; Ca, calcium, P, phosphorus; TA, thyroid adenoma; MG, multinodular goiter; CKD, chronic kidney disease; RL, renal
lithiasis; UR, unrelated; OP, osteoporosis; C, samples from patients with unaffected parathyroid glands; D, samples from patients with diffuse hyperparathyroidism; N,
samples from patients with nodular secondary hyperparathyroidism.
aFailed transplant; bThree years before parathyroidectomy; cSeven years before parathyroidectomy; dFourteen years before parathyroidectomy; eChronic kidney
disease of unkown origin; fChronic kidney disease from glomerulonephritis, gChronic kidney disease from interstitial nephropathy; hChronic kidney disease from
nephroangiosclerosis,
Array technologies allow an accurate and comprehen-
sive way for the simultaneous analysis of the expression
of thousands of genes and have been recently used in
several fields [15, 16]. Thus, to clarify the gene expression
changes common in the progression of secondary hyper-
parathyroidism, over 8500 genes have been analyzed by
oligonucleotide microarray in parathyroid glands with ei-
ther diffuse or nodular hyperplasia removed from renal
patients. Both samples and genes were classified by a two-
way clustering analysis and genes that were differentially
expressed between diffuse and nodular secondary hyper-
parathyroidism were identified. Real-time quantitative
polymerase chain reaction (PCR) was then used for con-
firmation of some randomly selected genes expression
values.
In order to further confirm the results, a gene
subtraction library was also constructed with another
set of diffuse and nodular parathyroid tissues. To
maximize the sensitivity of the differential screen-
ing, both a forward and reverse subtraction were
performed.
Also, a comparison between the genetic profile of
secondary and primary hyperparathyroidism was ob-
tained in order to see the differences of both patho-
logic states of the parathyroid glands at the genetic
level.
METHODS
Tissue samples and RNA preparation
A total of 34 nodular and 18 diffuse parathyroid glands
were obtained with informed consent from renal patients
who underwent parathyroidectomy at Hospital Gregorio
Maran˜o´n (Madrid, Spain), Hospital Clinic (Barcelona,
Spain), Hospital San Cecilio (Granada, Spain), Hospital
Curry Cabral (Lisboa, Portugal), Hospital Geral Santo
Antonio (Oporto, Portugal), and Complexo Hospitalario
(Ourense, Spain) between 2001 and 2003. All the patients
had chronic kidney disease, with PTH serum values span-
ning from 500 to 2500 pg/mL. Two normal parathyroid
glands obtained from thyroidectomies and nine parathy-
roid adenomas were also obtained from Hospital Gre-
gorio Maran˜o´n. Clinical data on these patients can be
found in Table 1. The study was approved by the Hos-
pital Universitario Central de Asturias Clinical Ethics
Committee.
All tissues were processed in a similar manner. Imme-
diately after parathyroidectomy, the parathyroid glands
were divided into two parts with special care for minimal
contamination of thyroid tissue. One was processed and
used for diagnosis and the other was submerged in an
RNAse inhibitor (RNAse Later) (Ambion, Austin, TX,
USA), to be used for the microarray analysis. If clear
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nodules were visible and isolable, they were removed
from the rest of the gland, always keeping one fragment
for diagnosis and another for the expression analysis.
Only 28 (14 diffuse and 14 nodular) out of 52 glands from
secondary hyperparathyroidism patients met a strict cri-
teria of excellent RNA quality and clear pathologic di-
agnosis. Only those glands with clear diagnosis of diffuse
or nodular growth after microscopy examination done by
the expert pathologist involved in this project, following
stringent guidelines of acceptance/rejection, were used
for expression analysis.
Tissues were homogenized and lysed directly in TRIzol
Reagent (Life Technologies, Helgerman, CT, USA). To-
tal RNA was extracted according to the manufacturer’s
instructions. After purification of the obtained RNA with
RNeasy Mini Kit (Qiagen, Valencia, CA, USA), the qual-
ity and quantity of the purified RNA were assessed by
formaldehyde agarose gel electrophoresis and quantified
by optical density. Only those samples that met strict cri-
teria of excellent quality RNA as described in Affymetrix
(Santa Clara, CA, USA) standard procedures were
used.
Biotin-labeled target synthesis reactions were per-
formed using standard protocols supplied by the man-
ufacturer (Affymetrix).
DNA microarray hybridization and analysis
Purified cRNA was fragmented to 200 to 300 mer
cRNA using a fragmentation buffer (40 mmol/L Tris ac-
etate, pH 8.1, 100 mmol/L KO acetate, and 30 mmol/L
MgO acetate) for 35 minutes at 94◦C. Fifteen micrograms
of fragmented cRNA were added to hybridization buffer
[100 mmol/L MES, 1 mol/L NaCl, 20 mmol/L ethylene-
diaminetetraacetic acid (EDTA), and 0.01% Tween-20)
and heated for 5 minutes at 99◦C and then at 45◦C for an-
other 5 minutes, before being hybridized in an oven for
16 hours at 45◦C with constant rotation of 60 rpm to the
Affymetrix Array. The hybridization was first done on
a Test 3 Affymetrix Array in order to test RNA qual-
ity; once RNA quality was confirmed, the cRNA was
hybridized to an Affymetrix GeneChip Focus Array
(Affymetrix) that represents over 8500 verified human
sequences from the NCBI RefSeq database.
Microarrays were processed in an Affymetrix
GeneChip Fluidic Station 400. Staining was done with
streptavidin-conjugated phycoerythrin (SAPE) followed
by amplification with a biotinylated antistreptavidin
antibody and a second round of SAPE, and then
scanned using an Agilent GeneArray Scanner (Agilent
Technologies, Palo Alto, CA, USA). The intensity of the
hybridization signal (expression value) was calculated
using Affymetrix GeneChip software MicroArray
Suite 5.0.
Validation of gene expression profiles by quantitative
reverse transcriptase (RT-PCR)
Twenty genes from the differentially expressed se-
quences found in the array analysis where randomly
selected and analyzed twice by quantitative RT-PCR
in each experimental sample as a validation system
with Custom-Assay MicroFluidic Cards (PE Applied
Biosystems, Foster City CA, USA) following manufac-
turer’s procedures. Two housekeeping expressed genes
[b-actin and glyceraldehyde-3-phosphate dehydrogenase
(GADPH)] were used as controls.
Construction of the subtraction expression library
Total RNA was extracted from each gland in a single-
step from 12 secondary hyperplasic parathyroid glands
(six diffuse and six nodular) with TRIreagent (Sigma-
Aldrich, St. Louis, MO, USA) and two equimolar pools
were created for diffuse glands and nodular glands. cD-
NAs were synthesized and amplified from the total RNA
with the SMART PCR cDNA Synthesis Kit (Clontech,
Palo Alto, CA, USA). The cDNAs were purified by the
QIAquick PCR Purification Kit (Qiagen, Valencia CA,
USA). The purified cDNAs were digested by RsaI, and
used directly for PCR subtraction library construction, as
described in PCR Select cDNA Subtraction Kit (Clon-
tech). Two subtractions were performed: a forward sub-
traction using the pool of diffuse samples as the driver
cDNA and a reverse subtraction where the pool of dif-
fuse samples acts as the tester cDNA.
After the subtraction and PCR selection, the result-
ing mixture, enriched for differentially expressed cDNAs,
was used for direct cloning, using the AdvanTAge PCR
Cloning Kit (Clontech) and following the manufacturer’s
instructions. The cloned cDNAs were sequenced in an
automatic sequencer (ABI Prism 310 Genetic Analyzer)
(PE Applied Biosystems) with T7 promoter primer. The
obtained sequences were compared with those deposits in
the NIH genetic sequence database by BLAST Sequence
Similarity Searching.
Statistical data analysis
Statistical analysis of the obtained data was performed
with both GenePublisher automatic DNA microarray
analysis system [17] and GeneSpring Analysis Software
(Silicon Genetics, Redwood City, CA, USA). The ratio
of nodular versus diffuse normalized expression values
corrected by the normal values was used as an estimated
fold change.
Before any statistical analysis was performed, all genes
were used for a Principal Component Analysis (PCA)
and class prediction analysis by K Nearest Neighbor
(KNN), and Nearest Centroid (NC) classifier. PCA
involves a mathematical procedure that transforms a
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Fig. 1. Gene expression intensity in diffuse parathyroid tissue com-
pared with nodular parathyroid tissue. The expression levels were an-
alyzed with GeneSpring 6.1 (Silicon Genetics, CA, USA). The upper
and lower boundaries represent a fourfold difference in the average
of the expression of each gene between diffuse and nodular samples.
Black circles represent sequences for which average expression in dif-
fuse samples was significantly higher or lower than it was in the nodular
samples (0.05). Approximately 0.6% of the 3270 sequences analyzed
for this figure displayed a statistically significant fourfold difference in
expression intensity between diffuse and nodular tissues. The axes scale
is logarithmic.
number of (possibly) correlated variables into a (smaller)
number of uncorrelated variables called principal compo-
nents. The first principal component accounts for as much
as the variability in the data as possible, and each suc-
ceeding component account for as much of the remain-
ing variable as possible. In KNN classifier, each sample is
compared to all other samples and the category assign-
ment of the three closest samples (k = 3) in Euclidean
gene expression space was used to predict its category.
NC classifier uses the closest class centroid to predict the
class of each sample.
Detailed data and protocols, according to the MI-
AME guidelines, can be found at http://www.hca.es/html/
websdepartam/ui/webjci.htm.
RESULTS
A two-way clustering analysis of diffuse and nodular
secondary hyperparathyroidism
Eight hyperplasic parathyroid tissues with diffuse
growth, eight late hyperplasic parathyroid tissues with
nodular growth, and two normal parathyroid tissues were
analyzed by high-density oligonucleotide microarray, and
expression data for over 8500 genes was obtained.
The relative expression for every gene was compared
between diffuse and nodular tissue. Figure 1 plots the av-
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Fig. 2. Class prediction analysis. (A) Principal Component Analysis
(PCA) showing all samples plotted according to their first two principal
components. (B) Predictions of the K Nearest Neighbor (KNN) and
Nearest Centroid (NC) classifiers. Abbreviations are: C (1 and 2), nor-
mal parathyroid tissue; D (1 to 8), diffuse hyperplasic tissue; and N (1
to 8), nodular hyperplasic tissue.
erage mRNA expression intensity of 3270 genes in sec-
ondary hyperparathyroidism samples with either diffuse
or nodular growth. Points lying above or below the upper
and lower boundaries represent samples in which expres-
sion in samples with diffuse growth was either fourfold
higher or fourfold lower, on average, than the samples
with nodular growth. Genes in which expression differ-
ences achieved statistical significance are depicted by a
black circle (P < 0.05).
PCA, based on all analyzed genes, grouped the sam-
ples accordingly to their diagnosis, as shown in Figure 2.
PCA eliminates the risk of outliers (due to bad quality
chips). Regarding class prediction analysis, KNN and NC
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Fig. 3. Hierarchic clustering of gene expression data. Each row rep-
resents a separate cDNA clone on the microarray and each column a
separate mRNA sample. The results presented represent the ratio of
hybridization of fluorescent cDNA probes prepared from each experi-
mental mRNA samples to a reference mRNA sample. These ratios are
a measure of relative gene expression in each experimental sample and
were depicted according to the color scale shown at the bottom, with
a continuum from dark green (lowest) to bright red (highest). As indi-
cated, the scale extends from fluorescence ratios of 0.25 to 4 (−2 to +2
in log base 2 units).
classifiers, also based on all genes, perfectly assigned each
sample to the proper histopathology group (Fig. 2).
A two-way clustering analysis, according to Pearson’s
correlation was performed with the expression data of
almost 4000 genes that passed prefiltering, producing a
characteristic gene profile pattern for normal, diffuse,
and nodular hyperplastic parathyroid tissue, as shown in
Figure 3.
Differently expressed genes in secondary
hyperparathyroidism
To identify genes that were differentially expressed
between diffuse and nodular secondary hyperparathy-
roidism, a Mann-Whitney U test to the raw data obtained
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Fig. 4. Cluster of relevant genes differentially expressed in diffuse and
nodular secondary hyperparathyroidism grouped by their function. (A)
Genes overespressed in nodular tissues. (B) Genes repressed in nodular
tissues. Each row represents a separate cDNA clone on the microarray
and each column a separate mRNA sample. The results presented rep-
resent the ratio of hybridization of fluorescent cDNA probes prepared
from each experimental mRNA samples to a reference mRNA sample.
These ratios are a measure of relative gene expression in each exper-
imental sample and were depicted according to the color scale shown
at the bottom, with a continuum from dark green (lowest) to bright red
(highest). As indicated, the scale extends from fluorescence ratios of
0.25 to 4 (−2 to +2 in log base 2 units).
by microarray analysis was applied, with standard cutoff
values for the ratio of 2.5 applied to extract only reliable
data. Sixteen genes were identified that showed higher ex-
pression in nodular-growth that in diffuse growth while
132 showed lower relative expression (P < 0.05) as shown
in Table 2 and Table 3. These genes were classified
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Table 2. Genes overexpressed in nodular tissues
Gene Fold
Genes overexpressed in nodular tissues symbol difference
DNA repair, maintenance, and apoptosis
Meiotic recombination 11
MRE11
RNA Processing and degradation
2′-5′-oligoadenylate synthetase-like
OASL 4.3
Guanylate binding protein 2 GBP2
Protein synthesis and processing
ADP-ribosylation factor 4-like
ARF4L 4.5
Eukaryotic translation initiation factor 4
gamma, 1
EIF4G1 4.2
Cell growth, maintentance, and
development
Cell division cycle 25C
CDC25C 4.3
FXDY domain containing ion transport
regulator 3
FXYD3 4.1
Gastrin-releasing peptide receptor GRPR 5.1
Melanoma antigen, family B, 2 MAGEB2 4.3
Microtubule-associated protein 1A MAP1A 4.5
Phosphatidylinositol glycan, class L PIGL 3.8
RAP1, GTPase activation protein 1 RAP1GA1 5.7
GPR1 binding protein GRSP1
RAF kinase inhibitor protein RKIP
Talin 1 TLN1
Cell signaling, signal transduction, and
transport
Calcium-binding
tyrosine-(Y)-phosphorilation
regulated
CABYR 4.6
Erythropoietin receptor EPOR 4.4
Phosphodiesterase 4C, cAMP-specific PDE4C 3.8
v-erb erythroblastic leukemia viral
oncogene homolog 3
ERBB3 3.6
Coatomer protein complex, subunit alpha COTA
Energy generation and metabolism
Carboxylesterase 2
CES2 4.1
Islet-specific glucose-6-phosphatase
catalytic subunit-related protein
IGRP 4.2
Cytochrome c oxidase II MTCO2
The genes are grouped by their function, displaying their names and
corresponding gene symbols. An estimated fold difference is also shown for the
differentially expressed genes found in the array analysis. Genes found in the
subtraction library are displayed in italic. Genes with expression values validated
by quantitiative reverse transcription-polymerase chain reaction (RT-PCR) are
displayed in bold.
in terms of function by referring to the literature and
OMIM databases, and their expression values were nor-
malized and corrected by the normal parathyroid tissue
expression values for each gene. As an estimation of the
overexpression or repression fold changes, nodular ex-
pression values were divided by diffuse values (overex-
pression) and diffuse expression values were divided by
nodular values (repression). Repression fold changes are
displayed as negative values for better understanding of
Table 3.
In order to verify the microarray analysis results, quan-
titative PCR using the same RNA used for microarray
analysis was performed. All the secondary hyperparathy-
roidism tissue samples were analyzed for 20 selected
genes. The obtained results showed a high concordance
rate between data obtained by real-time PCR and data
obtained by microarray in all samples and genes.
Some relevant genes involved in key cellular processes,
such as genetic stability, growth, and tumorigenesis were
highlighted from the two-way clustering analysis and are
displayed separately and grouped by gene function in
Figure 4.
The subtraction library performed with diffuse and
nodular parathyroid tissue total mRNA samples pro-
duced 34 overexpressed and 40 repressed genes in the
diffuse versus nodular expression comparison. Those
genes with known function and relevant to the study
are displayed in Table 2 and Table 3, together with those
described in the array analysis. Some genes, especially
those related to energy generation, protein synthesis,
and tumor-related genes, like some adenosine triphos-
phate (ATP) synthases and ribosomal proteins had been
found significantly repressed in the array analysis and also
identified as repressed in the subtraction library analysis.
Other genes, like some related to DNA repair and RNA
processing, were found in the subtraction library only, but
a more detailed analysis showed that those genes were
also repressed in the microarray study but did not pass
the restrictive criteria applied (cutoff values of 2.5 for the
raw data ratio).
Neither DNA arrays, the subtraction library, nor real-
time PCR showed significant differences between the
expression of calcium-sensuing receptor (CaSR) and vi-
tamin D receptor (VDR) receptors in diffuse and nodular
secondary hyperparathyroidism, although both of them
were clearly down-regulated when compared with nor-
mal parathyroid tissue (Fig. 5).
To establish the gene expression profile comparison
between primary and renal secondary hyperparathy-
roidism, a new two-way clustering analysis according
to Pearson’s correlation was performed. As shown in
Figure 6, the algorithm was able to perfectly group
parathyroid adenomas far from secondary hyperparathy-
roidism samples. To further expose the differences be-
tween hyperparathyroidism from both origins (primary
and secondary), some relevant genes have been selected
and analyzed using the expression values obtained with
quantitative RT-PCR. Figure 7 shows the representation
of the relative expression levels of these genes in parathy-
roid adenomas and in diffuse and nodular secondary
hyperparathyroidism. For some genes, the expression val-
ues are consonant in both primary hyperparathyroidism
and advanced nodular hyperplasia (ADAM23 and p21)
while other genes show different expression tendencies
(MEN1 and GRPR) and others are clearly differential,
like FLNB, up-regulated in adenomas but showing no
variation in secondary hyperparathyroidism (either in
diffuse or in nodular conditions).
DISCUSSION
In this study, the gene expression profile of secondary
hyperparathyroidism has been thoroughly analyzed with
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Table 3. Genes repressed in nodular tissues
Genes repressed in nodular tissues Gene symbol Fold difference
DNA repair, maintenance, and apoptosis
APMCF1 protein APMCF1 −4.7
DNA polymerase beta POLB −4.2
Peroxiredoxin 2 PRDX2 −4.1
Superoxide dismutase 1 SOD1 −4.4
Thioredoxin-like, 32 kD TXNL −3.6
Thyroid autoantigen 70 kD G22P1 −5.3
Transaldolase 1 TALDO1 −3.8
DNA damage binding protein 1 DDB1
X-ray repair protein 1 XRCC1
RNA synthesis, processing, and maintenance
Elongin B TCEB2 −4.2
Heterogeneous nuclear ribonucleoprotein D AUF1 −4.3
Scaffold attachment factor A SAFA −3.9
Small nuclear ribonucleoprotein polypeptide E SNRPE −6.1
Poly(A) binding protein PABPC1
Protein synthesis and processing
Chaperonin HSPD1 −3.7
DnaJ (Hsp40) homolog, subfamily C, member 7 TPR2 −7.7
Eukaryotic translation elongation factor 1 EEF1 −3.5
Eukaryotic translation initiation factor 3, subunit 3 gamma, 40 kD EIF3S3 −4.2
Lysyl-tRNA synthetase KARS −4.9
Nascent-polypeptide-associated complex alpha polypeptide NACA −4.2
Prefoldin 5 PFDN5 −4.4
Ribosomal protein L7 RPL7 −4.4
Ribosomal protein L9 RPL9 −4.6
Ribosomal protein L14 RPL14 −4.2
Ribosomal protein L22 RPL22 −3.8
Ribosomal protein L27 RPL27 −3.7
Ribosomal protein L27A RPL27A −4.6
Ribosomal protein L29 RPL29 −5.0
Ribosomal protein L32 RPL32 −3.6
Ribosomal protein L34 RPL34 −5.2
Ribosomal protein L35 RPL35 −4.1
Ribosomal protein L41 RPL41 −3.8
Ribosomal protein S3 RPS3 −6.4
Ribosomal protein S3A RPS3A −4.5
Ribosomal protein S7 RPS7 −5.5
Ribosomal protein S13 RPS13 −3.9
Ribosomal protein S15A RPS15A −5.6
Ribosomal protein S21 RPS21 −6.4
Ribosomal protein S23 RPS23 −3.7
Ribosomal protein S24 RPS24 −3.8
Ribosomal protein S25 RPS25 −4.9
Ribosomal protein S28 RPS28 −4.2
Ribosomal protein S29 RPS29 −5.6
Ribosomal protein S30 RPS30 −4.7
Ribosomal protein, large P2 RPLP2 −4.6
Threonyl-tRNA synthetase TARS −4.8
Oncogenes and tumor suppressor genes
Cullin 3 CUL3 −4.3
TRK-fused gene TFG −4.2
Tumor protein D52 TPD52 −5.2
Energy generation and metabolism
2, 4-Dienoyl CoA reductase 1 DECR1 −4.1
Accessory protein BAP31 BCAP31 −5.9
Alg5 ALG5 −4.6
Amylo-1, 6-glucosidase, 4-alpha-glucanotransferase AGL −4.5
ATP synthase F0 complex, subunit C (subunit 9) isoform 3 ATP5G3 −5.9
ATP synthase F0 complex, subunit C (subunit 9), isoform 2 ATP5G2 −7.4
ATP synthase F0 complex, subunit F6 ATP5J −4.7
ATP synthase F1 complex, alpha subunit, isoform 1 ATP5A1 −5.8
ATP synthase F1 complex, O subunit ATP5O −5.3
ATPase lysosomal 42 kD, V1 subunit C isoform 2 ATP6V1C2 −4.9
ATPase lysosomal interacting protein 2 ATP6IP2 −4.8
Autophagy Apg3p/Aut1p-like APG3 −4.6
Cytochrome C oxidase subunit Vb COX5B −3.7
Cytochrome C oxidase subunit VIc COX6C −4.7
(continued)
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Table 3. (continued)
Genes repressed in nodular tissues Gene symbol Fold difference
Hydroxysteroid (17-beta) dehydrogenase 4 HSD17B4 −3.7
Lactate dehydrogenase A LDHA −3.9
Low molecular mass ubiquinone-binding protein (9.5 kD) QP-C −5.0
Malate dehydrogenase 1, NAD MDH1 −5.2
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 7.5 kD NDUFA1 −5.6
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, 8 kD NDUFA2 −3.7
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4, 9 kD NDUFA4 −5.1
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6, 14 kD NDUFA6 −5.4
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 4, 15 kD NDUFB4 −4.3
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5, 16 kD NDUFB5 −5.3
NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1, 6 kD NDUFC1 −5.0
NADH-coenzyme Q reductase NDUFS3 −5.1
Pyrophosphatase PP −5.4
Squalene epoxidase SQLE −4.6
Succinate dehydrogenase complex, subunit D protein SDHD −5.5
Succinate-CoA ligase, GDP-forming, alpha subunit SUCLG1 −4.2
Ubiquinol-cytochrome C reductase core protein I UQCRC1 −4.4
Ubiquinol-cytochrome C reductase hinge protein UQCRH −5.1
Vitamin A responsive JWA −4.5
Peptidases and protein degradation
Glyoxalase I GLO1 −5.1
Integral membrane protein 2C ITM2C −5.0
Proteasome (prosome, macropain) 26S subunit, ATPase, 1 PSMC1 −4.3
Proteasome (prosome, macropain) 26S subunit, ATPase, 5 PSMC5 −4.2
Proteasome (prosome, macropain) 26S subunit, non-ATPase, 4 PSMD4 −4.6
Proteasome (prosome, macropain) subunit, alpha type, 4 PSMA4 −3.7
Proteasome (prosome, macropain) subunit, beta type, 1 PSMB1 −4.5
Proteasome (prosome, macropain) subunit, beta type, 4 PSMB4 −4.1
Ubiquilin 2 UBQLN2 −4.7
Ubiquitin protein ligase E3A UBE3A −5.5
Ubiquitin specific protease 1 USP1 −4.6
Ubiquitination factor E4A UBE4A −4.7
Cystatin 4 CST4
Cell signaling, signal transduction, and transport
Endosulfine alpha ENSA −3.8
Fibroblast growth factor 13 FGF13 −10.1
GDP dissociation inhibitor 2 GDI2 −4.6
Glucose regulated protein, 58kDa GRP58 −4.1
Macrogolgin 1 GOLGB1 −4.5
Tom7 homolog TOM7 −6.0
Insulin-degrading enzyme IDE −4.3
Jagged 1 JAG1 −5.3
Metaxin 2 MTX2 −3.6
Mitochondrial carrier homolog 1 MTCH1 −3.9
Protein kinase, interferon-inducible dsRNA dependent activator PRKRA −4.5
Protein transport SEC61 alpha subunit isoform 1 SEC61A1 −3.8
Protein tyrosine phosphatase, receptor type, A PTPRA −5.0
RNA binding motif, single stranded interacting protein 1 RBMS1 −4.3
RNA-binding protein regulatory subunit DJ-1 −4.3
Signal recognition particle 14 kD SRP14 −3.9
Translocase of inner mitochondrial membrane 8 TIMM8B −3.7
Translocase of outer mitochondrial membrane 20 TOMM20 −5.3
Ring ﬁnger protein 34 RNF34
Hypoxanthine guanine phosphoribosyltransferase 1 HPRT1
Transcription activators
Core-binding factor, beta subunit CBFB −4.2
General transcription factor IIIA GTF3A −5.0
High-mobility group nucleosome binding domain 1 HMGN1 −4.3
Nuclear factor of activated T-cells calcineurin-dependent 3 NFATC3 −8.1
Cell growth, maintenance, and development
Bromodomain containing 7 BRD7 −5.9
BX1 BX1 −4.0
Ceroid-lipofuscinosis, neuronal 5 CLN5 −4.6
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 1 DDX1 −6.4
DEAD/H (Asp-Glu-Ala-Asp/His) box Polypeptide 5 DDX5 −3.5
Host cell factor homolog LCP −3.8
Male-enhanced antigen MEA −4.2
Ovarian carcinoma antigen CA125 M17S2 −5.1
(continued)
Santamarı´a et al: Gene expression proﬁle of severe secondary hyperparathyroidism 2275
Table 3. (continued)
Genes repressed in nodular tissues Gene symbol Fold difference
Mitochondrial ribosomal protein L40 MRPL40 −5.1
MO25 protein MO25 −4.5
Thyroid hormone receptor interactor 12 TRIP12 −5.5
Vesicle transport through interaction with t-SNAREs homolog 1B VTI1B −5.1
Villin 2 (Ezrin) VIL2 −5.4
ATPase Ca2+ transporting SERCA2
Heat-shock 90 kD protein 1 HSPCA
HIV-1 Rev binding protein HRB
Tropomyosin 1 TPM1
Unknown function
Chromosome 14 open reading frame 2 C14orf2 −3.8
Hypothetical protein HSPC117 HSPC117 −4.2
Hypothetical protein MGC8721 MGC8721 −6.8
PP1201 protein PP1201 −5.0
Putative secreted protein ZSIG11 ZSIG11 −3.8
Small acidic protein SMAP −6.4
The genes are grouped by their function, displaying their names and corresponding gene symbols. An estimated fold difference is also shown for the differentially
expressed genes found in the array analysis. Fold changes are given negative numbers to better express the repression nature of the values. Genes found in the subtrac-
tion library are displayed in italic. Genes with expression values validated by quantitiative reverse transcription-polymerase chain reaction (RT-PCR) are displayed in bold.
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Fig. 5. Relative expression levels of CaSR
and VDR mRNA measured by reverse
transcription-polymerase chain reaction (RT-
PCR). The results have been normalized with
the internal housekeeping control genes and
the normal parathyroid tissue levels have
been subtracted to show only the differences
between diffuse (light gray) and nodular (dark
gray) secondary hyperparathyroidism. Each
vertical bar represents one analyzed sample.
Error bars represent the standard deviation.
CaSR, calcium-sensing receptor; VDR, vita-
min D receptor.
the aim to detect specific genomic changes associated
with progression of renal hyperparathyroidism. Diffuse
and nodular secondary hyperparathyroidism were dis-
tinguished by gene expression profiling alone, indicat-
ing that array analysis combined with gene subtrac-
tion analysis represents a useful tool for studying the
changes of gene expression involved in the progression
and severity of secondary hyperparathyroidism. Nev-
ertheless, as in some cases, monoclonally growing tis-
sue may present as diffuse hyperplasia, yet with clonal
growth, the results should be considered as a progres-
sion from diffuse or early monoclonal growth to fully
developed nodules consisting of monoclonal parathyroid
cells.
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Nodular tissue Diffuse tissue Normal Adenomas
−2 −1 0 1 2
Fig. 6. Hierarchical clustering of gene expression data. The figure shows the comparing profiles between normal parathyroid glands and samples
from patients with primary and secondary hyperparathyroidism. Each row represents a separate cDNA clone on the microarray and each column a
separate mRNA sample. The results presented represent the ratio of hybridization of fluorescent cDNA probes prepared from each experimental
mRNA samples to a reference mRNA sample. These ratios are a measure of relative gene expression in each experimental sample and were depicted
according to the color scale shown at the bottom, with a continuum from dark green (lowest) to bright red (highest). As indicated, the scale extends
from fluorescence ratios of 0.25 to 4 (−2 to +2 in log base 2 units).
Genes associated with cell growth, apoptosis,
and tumorigenesis
As expected, nodular hyperplasia presents an overall
increase in the expression of genes involved in the acti-
vation of cell proliferation pathways. The overexpression
of genes like CDC25C (mitosis inducer [18]), GRPR (au-
tocrine loop for growth [19]), and the repression of others
like APMCF1 (apoptosis [20]), TPR2 (cell cycle suppres-
sor [21]), BRD7 (cell growth suppressor [22]), and CUL3
(cyclin degradation [23]) confirms that processes which
facilitate the growth of the gland are occurring in the
nodules. In addition, overexpression of PDE4C (AMPc
regulator [24]) is also relevant as it has been related to
hypertrophy of some tissues [25].
Although primary hyperparathyroidism can some-
times involve parathyroid carcinomas, secondary
hyperparathyroidism very seldom leads to malignancy.
The expression profile of nodular hyperplasia reflects
changes in some genes involved in benign tumoral
growth. Overexpression of RKIP, whose decreased
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Fig. 7. Relative expression levels of several
genes differentially expressed in primary and
secondary hyperparathyroidism by reverse
transcription-polymerase chain reaction (RT-
PCR). The results have been normalized with
the internal housekeeping control genes and
the normal parathyroid tissue levels have
been subtracted to show only the differ-
ences between diffuse (light gray) and nodu-
lar (medium gray) secondary and primary
(dark gray) hyperparathyroidism. Each verti-
cal bar represents the average value for each
kind of tissue. Error bars represent the stan-
dard deviation. (A) Genes showing similar ex-
pression patterns in adenomas and nodular
hyperplasia. (B) Genes with different expres-
sion patterns in adenomas and nodular hy-
perplasia. (C) Gene with opposed expression
profile pattern in primary and secondary hy-
perparathyroidism. Gene symbols: ADAM23,
a disintegrin and metalloproteinase domain
23; ARF4L, ADP-ribosylation factor 4-like;
p21, cyclin-dependent kinase inhibitor 1A;
RAP1GA1, RAP1, GTPase-activating pro-
tein 1; OASL, 2′,5′oligoadenylate synthetase-
like; DSCR1, down syndrome critical re-
gion gene 1; EPOR, erythropoietin receptor;
FXYD3, FXYD domain-containing ion trans-
port regulator 3; GRPR, gastrin-releasing
peptide receptor; MAP1A, microtubule-
associated protein 1A; MEN1, multiple en-
docrine neoplasia, type I; CCND1, cyclin D1;
FLNB, filamin B.
expression is related to angiogenesis, vascular invasion,
and apoptosis protection [26], is a good example of the
metastatic suppressor mechanisms found in secondary
hyperparathyroidism. Likewise, the overexpression of
RAP1GA1 (a tumor suppressor gene [27]) and the
repression of genes usually overexpressed in tumor pro-
cesses (VIL2 [28] and TPD52 [29]) confirm the benign
character of the type of growth observed in nodular and
advanced cases of secondary hyperparathyroidism.
Genes associated with DNA, RNA, and protein
instability, processing, and location are differentially
expressed in nodular hyperplasia
According to the results, nodular parathyroid hyper-
plasia seems to be characterized by gene repression, as
opposed to the gene overexpression observed in primary
hyperparathyroidism. The changes in gene expression
observed between diffuse and nodular secondary hyper-
plasia involve several genes that play key roles in DNA
stability and repair, RNA synthesis and degradation, and
protein synthesis, processing, and transport.
One of the main concerns of cell biology is to main-
tain the genetic material in perfect condition, which is
done by combining adequate structural architecture with
protective measures and repair systems. The results of
this study support the concept that as secondary hyper-
parathyroidism worsens, those three mechanisms become
progressively and severely compromised.
Reactive oxygen species and free radicals that are pro-
duced during normal metabolism have the potential to
damage cellular macromolecules. Defenses against such
damage include a number of antioxidant enzymes that
specifically target the removal or dismutation of the re-
active agents. The repression of genes related to protect-
ing the genetic material from these reactive species like
PRDX2 (oxidative stress protection [30]) and TALDO1
(reduce equivalents to protect cellular integrity from re-
active oxygen intermediates [31]) coexists with repression
of POLB (base excision repair [32]), DDB1 (ultraviolet
damage repair [33]) and XRCC1 (single-strand breaks
repair [34]). The base excision repair pathway is believed
to maintain genomic integrity by repairing DNA damage
arising by oxidizing and alkylating agents like those that
escape the control of peroxiredoxins and transaldolases.
The interaction between POLB and XRCC1 has proved
mandatory for the efficiency of the base excision repair
system [35]. Furthermore, the reduced expression in hy-
perplasic nodules of other genes related to the architec-
ture of DNA, like SAFA [36] and the overexpression of
genes related to chromosome breaks like MRE11 [37]
perfectly correlates with the large amount of chromo-
somal aberrations found in parathyroid glands removed
from patients with refractory secondary hyperparathy-
roidism [14].
Not only DNA stability seems compromised in nodu-
lar hyperplasia. Overexpression of genes related to RNA
degradation like OASL (synthesis of RNA degrading
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enzymes [38]) and repression of genes related to RNA
stability like DDX1 and DDX5 (RNA helicases [39])
also indicates a modified pattern in the transference of
genetic information. It must be pointed out the repres-
sion of AUF1, involved in ARE-mediated RNA turnover.
Its reduced expression favors longer half-lives of ARE-
containing sequences, like cytokines, thus promoting cell
proliferation; it has also been described a role of AUF1
in stabilizing PTH mRNA through binding to its 3′ un-
translated region in hypocalcemic conditions [40]. The
repression of a gene involved in poly(A) shortening and
translation initiation like PABPC1 [41] may also indicate
a failure in the proper processing of mRNA and the ini-
tiation of translation.
A similar situation can be inferred for protein synthe-
sis and processing. Genes closely related to the proper
folding of proteins like PFDN5 (stabilizes proteins prior
to folding [42]) and HSPD1 (involved in folding and as-
sembly [43]) are repressed in the advanced parathyroid
hyperplasia, along with others related to protein desti-
nation like TOM20 (mitochondrial protein import recep-
tor [44]), TIMM8B (translocase of inner mitochondrial
membrane [45]) and NACA (sorting of nascent polypep-
tides [46]).
VDR and CaSR in secondary hyperparathyroidism
progression
The abnormal control of PTH secretion in chronic
kidney disease has been attributed in part to down-
regulation of the CaSR and VDR in hyperplastic parathy-
roid tissue, with reduced levels of both receptors in
parathyroid nodules. Our results show an important de-
crease in mRNA levels in these receptors both in diffuse
and nodular tissue, suggesting that at least in these two ad-
vanced stages of the progression of the disease no changes
in expression are detected. Considering the compro-
mised RNA stability and protein synthesis, processing,
and destination in the cells of the parathyroid nodules it is
possible to speculate that the variation found at the pro-
tein level of these receptors is due to posttranscriptional
regulation.
Comparison with primary hyperparathyroidism
When comparing the expression profile of primary
and secondary hyperparathyroidism, the results clearly
distinguish them as different entities. At first sight, a
major gene repression in the progression of secondary
hyperparathyroidism from diffuse to nodular hyperplasia
when compared with primary adenomas is observed. Fur-
thermore, the different origin and onset of primary and
secondary hyperparathyroidism clearly marks their evo-
lution, as stated by the different expression behavior of
some genes representative of the primary and secondary
disorders, like MEN1 or GRPR. Similar results have been
obtained by Morrison et al [47], although the microarrays
analysis does not separate diffuse from nodular glands,
thus observing some heterogenicity among the eight hy-
perplasic samples from renal patients. On the other hand,
heterogenicity among parathyroid adenomas and carci-
nomas has also been observed by other authors [48] using
tissue arrays.
CONCLUSION
All these results highlight the multiple, complex, and
integrated cellular mechanisms involved in advanced sec-
ondary hyperplasia: (1) cell growth is highly promoted in
the nodules; (2) DNA stability is severely compromised
because of failure in the protective mechanism and re-
pair systems; (3) RNA synthesis and stability is also in
jeopardy; and (4) protein synthesis, processing and desti-
nation is clearly impeded by means of failure in folding,
assembly, and sorting of the polypeptides.
These alterations in gene expression found in the se-
vere cases of nodular secondary hyperparathyroidism are
related to irreversible changes that could not be solved by
any kind of medical treatment. Adequate and early man-
agement of secondary hyperparathyroidism in chronic
kidney disease will be the only way to avoid these changes.
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